IFN/RBV treatment induced neutropenia and its correction with neupogen in patients with hepatitis C.

IFN/RBV treatment induced neutropenia and its correction with neupogen in patients with hepatitis C.
复制标题

丙型肝炎患者中 IFN/RBV 治疗引起的中性粒细胞减少症及其用 Neupogen 的纠正。

DOI:
--
复制
发表时间:
2007
影响因子:
--
通讯作者:
T. Tsertsvadze
T. Tsertsvadze
中科院分区:
--
文献类型:
--
作者:
L. Sharvadze;N. Gochitashvili;A. Tophuria;N. Bolokadze;T. Tsertsvadze

文献摘要

被引文献

相似文献

The aim of the study was to observe the frequency of neutropenia during Pegylated Interferon/Ribavirin therapy in patient with chronic hepatitis C; to compare the efficacy of two strategies of management of neutropenia--with Interferon dose modification and with Neupogen administration; to compare the effectiveness rate of sustained viral response (SVR) in patients with Pegylated Interferon dose modification and in patients treated by using granulocyte colony-stimulating factor G-CSF-filgrastim. (Neupogen). Study enrolled 47 patients with chronic active hepatitis C, aged 23-64. (38 male and 9 female). All patients had HCV genotype 1b. Significant neurtopenia (ANC<750 mm3) and severe neurtopenia (ANC<500 mm3) developed in 41 of 47 patients (87%). 41 patients with neurtopenia were randomized into two groups. The first group--22 patients who received granulocyte colony-stimulating factor (G-CSF, or filgrastim) 300 mcg s/c weekly for correction of neutropenia and the second group--19 patients treated either with Interferon dose reduction or temporarily inhibit of Interferon treatment. In all 22 patients of the first group neutropenia was normalized without reduction and/or inhibit of Pegylated interferon. Neupogen was well tolerated and in all 22 patients the improvement of quality of life (QOL) was observed. It was concluded that dose reduction or temporary inhibit of Pegylated Interferon in the second group negatively acts on antiviral treatment response in patients with HCV genotype 1. In patients with PEG-IFN/RBV therapy Neupogen effectively manages neutropenia and gives opportunity to maintain interferon dose (without reduction). Neupogen has the potential to improve adherence rates, which may in turn improve SVR.